Pfizer (PFE) Non Operating Income (2010 - 2026)

Pfizer has disclosed Non Operating Income across 17 years of filings, most recently posting -$861.0 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 9.65% year-over-year to -$861.0 million; the TTM figure through Mar 2026 stood at -$6.6 billion (down 122.29% YoY), while the FY2025 annual figure was -$6.7 billion, down 53.24% from the prior year.
• Non Operating Income grew to -$861.0 million in Q1 2026, from -$4.5 billion in the prior quarter.
• Over the last five years, Non Operating Income for PFE reached as high as $159.0 million in Q4 2023 and fell as low as -$4.5 billion in Q4 2025.
• The 5-year median for Non Operating Income is -$517.0 million (2025), against an average of -$726.6 million.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 109.72% — and 2024, when it slumped 1576.0%.
• A 5-year view of Non Operating Income shows it stood at $59.0 million in 2022, then soared by 169.49% to $159.0 million in 2023, then sank by 252.83% to -$243.0 million in 2024, then slumped by 1757.61% to -$4.5 billion in 2025, then soared by 80.93% to -$861.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$861.0 million, -$4.5 billion, and -$517.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.